Symrise and Lubrizol bet on Singapore for faster Asia innovation
Singapore is becoming a key innovation hub for the personal care industry, with major suppliers expanding their regional R&D and creative capabilities in the city-state. Symrise and Lubrizol are the latest to strengthen their Singapore presence, aiming to speed up customer collaboration and deliver solutions tailored to fast-growing Asian markets.
Lundbeck starts Phase 2; Rewind secures funding; Beactica picks a degrader
Lundbeck starts Phase 2 Parkinson’s trial. Lundbeck has begun Phase 2 testing of Lu AF28996 after an open-label Phase 1b study suggested improved motor control in advanced Parkinson’s disease. Among 34 participants treated for six weeks, daily time with good symptom control and without troublesome involuntary movements increased by 3.6 hours, alongside reduced levodopa use. Most adverse events were mild, with nausea, dizziness and falls the most common. The oral dopamine receptor agonist could help address persistent motor fluctuations, but efficacy requires confirmation. The placebo-controlled DARE2 trial will enroll approximately 150 adults. Go deeper.
Bluemercury revamps Lune+Aster to make luxury beauty “uncomplicated”
Bluemercury, a US-based luxury beauty retailer, has revealed that its proprietary makeup brand Lune+Aster is undergoing an identity evolution and will introduce arange of versatile color products for lips, cheeks, and eyes.
Switch Bio partners with Bayer to advance ‘switchable’ tech for biofertilizers
Switch Bioworks—a startup engineering nitrogen fixing microbes that colonize plant roots before switching on ammonia pro…
Undecimal raises $18M to take siRNA beyond the liver
The spinout from Eleven Therapeutics operates in Cambridge, England, and Tel Aviv, Israel. 4BIO Capital and IQ Capital co-led the round, joined by Verve Ventures, Harel Tech, Entree Capital, Kerna Ventures and Saras Capital.
LVMH beauty sales hold steady in Q3 as Sephora drives retail growth
LVMH (Moët Hennessy Louis Vuitton) has reported organic growth in its Perfumes & Cosmetics business and Selective Retailing, led by Sephora, in Q3 2026.
Roche’s China shopping spree continues with $1B Rona obesity pact
Why it matters: The Swiss drugmaker is expanding its search for treatments that reduce fat while preserving lean mass. The agreement also puts Roche alongside Arrowhead Pharmaceuticals and GSK in pursuing ALK7, a target that could complement GLP-1 drugs.
Fine fragrances boost Givaudan beauty sales
Givaudan’s organic sales outpaced market expectations by almost twofold in Q3. The company’s like-for-like sales grew 8.6% in the quarter, compared to analyst expectations of 4.7%.
🎥 ClimateCrop bets on starch ‘off switch’ to improve crop performance
Neutralizing the “off switch” for starch production in plants could be the key to unlocking higher yields and boos…
Enodia lands $500M Pfizer deal to target proteins at the point of synthesis
Why it matters: The targeted protein degradation field is gaining momentum, and this Pfizer-Enodia collaboration offers another example of how large pharmaceutical companies are increasingly willing to place strategic bets on this emerging therapeutic category.